Sphingosine kinase inhibitors as maintenance therapy of glioblastoma after ceramide-induced response

Anticancer Research

Volumn 36, Issue 5, 2016, Pages 2085-2096

  Sordillo, Laura A ^a   Sordillo, Peter P ^a   Helson, Lawrence ^a  

^a SignPath Pharma Inc   (United States)

Author keywords

Ceramide; Chemotherapy; Glioblastoma; Maintenance therapy; Review; Sphingolipid rheostat; Sphingosine 1 phosphate; Sphingosine kinase; Tumor recurrence

Indexed keywords

CERAMIDE; PHOSPHOTRANSFERASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PHOSPHOTRANSFERASE; SPHINGOSINE KINASE;

GLIOBLASTOMA; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; ENZYMOLOGY; METABOLISM; MOUSE;

ANIMALS; BRAIN NEOPLASMS; CERAMIDES; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; MICE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR);

EID: 85006286820     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. American Brain Tumor Association. http://www.abta.org/braintumor-information/types-of-tumors/glioblastoma.html
2. National Brain Tumor Society. http://braintumor.org/braintumor-information/understanding-brain-tumors/tumor-types/
3. Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, Raza SM, Pascual-Gallego, Ibrahim A, Hernandez-Hermann M, Gomez L, Ye X, Weingart JD, Olivi A, Blakeley J, Gallia GL, Lim M, Brem H and Quinones-Hinojosa A: Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol 16: 113-122, 2013.
4. Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM and Buckner JC: A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: The impact of the extent of resection on quality of life and survival. Neurosurgery 57(3): 495-504, 2005.
5. Park JK, Hodges T, Arko L, Shen M, Iacono DD, McNabb A, Bailey NO, Kreisi TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA and Black PM: Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 28(24): 3838-3843, 2010.
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 10(5): 459-466, 2009.
7. Darefsky AS, King JT Jr. and Dubrow R: Adult glioblastoma multiforme survival in the temozolomide era: A populationbased analysis of surveillance, epidemiology, and end results registries. Cancer 118: 2163-2172, 2011.
8. Cohen MH, Johnson JR and Pazdur R: Food and drug administration drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11: 6767-6771, 2005.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 352: 987-996, 2005.
10. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH and Friedman HS: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25: 4722-4729, 2007.
11. Taal W, OOsterkamp H, Walenkamp A, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, Dinjens WN, Enting RH, Taphoorn MJ, van den Berkmortel FW, Jansen RL, Brandsma D, Bromberg JE, van Heuvel I, Vernhout RM, van der Holt B and van den Bent MJ: Singleagent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncology 15(9): 943-953, 2014.
12. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L and Cloughesy T: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722, 2014.
13. Lefranc, F, N. Sadeghi, Camby I, Metens T, Dewitte O and Kiss R: Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 6(5): 719-32, 2006.
14. Wick W, Platten M and Weller M: New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11: 69-79, 2009.
15. Mason WP and Cairncross JG: Drug insight: Temozolomide as a treatment for malignant glioma - impact of a recent trial. Nat Clin Pract Neurol 1: 88-95, 2005.
16. Villano JL, Seery TE and Bressler LR: Temozolomide in malignant gliomas: Current use and future targets. Cancer Chemother Pharmacol 64: 647-655, 2009.
17. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N and Yang I: Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 307-322, 2012.
18. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE and Aboagye EO: A new model for prediction of drug distribution in tumor and normal tissues: Pharmaco-kinetics of temozolomide in glioma patients. Cancer Res 69: 120-127, 2009.
19. Leroy H, Vermandel M, Tetard M, Lejeune J, Mordon S and Reyns N: Interstitial photodynamic therapy and glioblastoma: Light fractionation study on a preclinical model: Preliminary results. Proc. SPIE 9305, Optical Techniques in Neurosurgery, Neurophotonics, and Optogenetics II: 93050D, 2015.
20. Sathornsumetee S and Rich JN: New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 6(7): 1087-104, 2006.
21. Okonogi N, Shirai K, Oike T, Murata K, Noda SE, Suzuki Y and Nakano T: Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme. Anticancer Res 35(3): 1229-1233, 2015.
22. Wang L, Zhang Y, Wu X and Yu G: Aquaporins: new targets for cancer therapy. Technol Cancer Res Treat pii: 15330346 15607693. [Epub ahead of print], 2015.
23. Cremesti AE, Goni FM and Kolesnick R: Role of sphingomyelinase and ceramide in modulating rafts: Do biophysical properties determine biologic outcome?. FEBS Lett 531(1): 47-53, 2002.
24. Dolgachev V, Farooqui MS, Kulaeva OI, Tainsky MA, Nagy B, Hanada K and Separovic D: De novo ceramide accumulation due to inhibition of its conversion to complex sphingolipids in apoptotic photosensitized cells. J Biol Chem 279(22): 23238-23249, 2004.
25. Kang MS, Ahn KH, Kim SK, Jeon HJ, Ji JE, Choi JM, Jung KM, Jung SY and Kim DK: Hypoxia-induced neuronal apoptosis is mediated by de novo synthesis of ceramide through activation of serine palmitoyltransferase. Cell Signal 22(4): 610-618, 2010.
26. Merrill AH Jr.: De novo sphingolipid biosynthesis: A necessary, but dangerous, pathway. J Biol Chem 277(29): 25843-25846, 2002.
27. Marchesini N and Hannun YA: Acid and neutral sphingomyelinases: Roles and mechanisms of regulation. Biochem Cell Biol 82(1): 27-44, 2004.
28. Mencarelli C and Martinez-Martinez P: Ceramide function in the brain: when a slight tilt is enough. Cell Mol Life Sci 70(2): 181-203, 2013.
29. Kitatani K, Idkowiak-Baldys J and Hannun YA: The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal 20(6): 1010-82008.
30. Selvam SP and Ogretmen B: Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance. Handb Exp Pharmacol 216: 03-27, 2013.
31. Obeid LM, Lindaric CM, Karolak LA and Hannun YA: Programmed cell death induced by ceramide. Science 259(5102): 1769-1771, 1993.
32. Zhang H, Desai NN, Olivera A, Seki T, Brooker G and Spiegel S: Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J CellBiol 114(1): 155-167, 1991.
33. Hannun YA and Obeid LM: Mechanisms of ceramide mediated apoptosis. Adv Exp Med Biol 407: 145-149, 1997.
34. Kawamura H, Tatei K, Nonaka T, Obinata H, Hattori T, Ogawa A, Kazama H, Hamada N, Funayama T, Sakashita T, Kobayashi Y, Nakani T and Izumi T: Ceramide induces myogenic differentiation and apoptosis in Drosophila Schneider cells. J Radiat Res 50(2): 161-169, 2009.
35. Venable ME, Lee JY, Smyth MJ, Bielawska A and Obeid LM: Role of ceramide in cellular senescence. J Biol Chem 270: 30701-30708, 1995.
36. MacKichan ML and DeFranco AL: Role of ceramide in lipopolysaccharide (LPS)-induced signaling. LPS increases ceramide rather than acting as a structural homolog. J Biol Chem 274(3): 1767-1775, 1999.
37. Yabu T, Shiba H, Shibasaki Y, Nakanishi T, Imamura S, Touhata K and Yamashita M: Stress-induced ceramide generation and apoptosis via the phosphorylation and activation of nSMase1 by JNK signaling. Cell Death Differ 22(2): 258-273, 2014.
38. Radeff-Huang J, Seasholtz TM, Chang JW, Smith JM, Walsh CT and Brown JH: Tumor necrosis factor alpha stimulated cell proliferation is mediated through sphingosine kinase dependent Akt activation and cyclin D expression. J Biol Chem 282(2): 863-870, 2007.
39. Zhang Y, Yao B, Delikat S, Bayoumy S, Lin X H, Basu S, McGinley M, Chan Hui PY, Lichenstein H and Kolesnick R: Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89(1): 63-72, 1997.
40. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S and Spiegel S: Sphingosine kinase expression increases intracellular sphingosine 1 phosphate and promotes cell growth and survival. J Cell Biol 147(3): 545-558, 1999.
41. Young MM, Kester M and Wang HG: Sphingolipids: Regulators of crosstalk between apoptosis and autophagy. J Lipid Res 54(1): 5-19, 2013.
42. An S, Zheng Y and Bleu T: Sphingosine 1phosphate induced cell proliferation, survival, and related signaling events mediated by G protein coupled receptors Edg3 and Edg5. J Biol Chem 275(1): 288-296, 2000.
43. Dobrowsky RT, Kamibayashi C, Mumby MC and Hannun YA: Ceramide activates heterotrimeric protein phosphatase 2A. J Biol Chem 268(21): 15523-155330, 1993.
44. Sentelle RD, Senkal CE, Jiang W, Ponnusamy S, Gencer S, Selvam SP, Ramshesh VK, Peterson YK, Lemasters JJ, Szulc ZM, Bielawski J and Ogretmen B: Ceramide targets autophagosomes to mitochondria and induces lethal mitophagy. Nat Chem Biol 8(10): 831-838, 2012.
45. Alesse E, Zazzeroni F, Angelucci A, Giannini G, Di Marcotullio L and Gulino A: The growth arrest and downregulation of cmyc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. Cell Death Differ 5(5): 381-389, 1998.
46. Beier D, Rohrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P and Beier CP: Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68(14): 5706-5715, 2008.
47. Cho DY, Lin SZ, Yang WK, Lee HC, Hsu DM, Lin HL, Chen CC, Liu CL, Lee WY and Ho LH: Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant 22(4): 731-739, 2013.
48. Sordillo PP and Helson L: Curcumin and cancer stem cells: Curcumin has asymmetrical effects on cancer and normal stem cells. Anticancer Research 35(2): 599-614, 2015.
49. Kalkan R: Glioblastoma stem cells as a new therapeutic target for glioblastoma. Clin Med Insights Oncol 9: 95-103, 2015.
50. Gao P, Peterson YK, Smith RA and Smith CD: Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS One 7(9): E44543, 2012.
51. Zhang Y, Wang Y, Wan Z, Liu S, Cao Y and Zeng Z: Sphingosine kinase 1 and cancer: A systematic review and metaanalysis. PLoS One 9(2): E90362, 2014.
52. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D'Andrea RJ and Vadas MA: An oncogenic role of sphingosine kinase. Curr Biol 10(23): 1527-1530, 2000.
53. Maceyka M, Harikumar KB, Milstien S and Spiegel S: Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22(1): 50-60, 2012.
54. Pyne S, Edwards J, Ohotski J and Pyne NJ: Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol 2: 168, 2012.
55. Morad SA and Cabot MC: Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 13: 51-65, 2013.
56. Reynolds CP, Maurer BJ and Kolesnick RN: Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206(2): 169-180, 2004.
57. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A and Ogretmen B: Sphingolipids and cancer: Ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 6(10): 1603-1624, 2010.
58. Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4(8): 604-616, 2004.
59. Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J, Hannun Y A and Obeid LM: Role for sphingosine kinase 1 in colon carcinogenesis. The FASEB J 23(2): 405-414, 2009.
60. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C and Bousquet C: Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8(4): 809-808, 2009.
61. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, Gutkind JS, Rivadulla MG and Curino AC: The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs 192(5): 314-313, 2010.
62. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA and Obeid LM: Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem 53(9): 1159-1166, 2005.
63. Nava VE, Hobson JP, Murthy S, Milstien S and Spiegel S: Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer mcf-7 cells. Exp Cell Res 281(1): 115-127, 2002.
64. Sukocheva OA, Wang L, Albanese N, Vadas MA and Xia P: Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol 17(10): 2002-2012, 2003.
65. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JV and Cuvillier O: Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 22(5): 971-979, 2008.
66. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, Levade T and Moreau-Gachelin F: Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106(5): 1808-1816, 2005.
67. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S. Geisslinger G, Holtrich U, Karn T and Kaufmann M: Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 112(1): 41-52, 2008.
68. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S and Geilen CC: Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: Role of Bcl-2 expression. Oncogene 24(1): 178-218, 2005.
69. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier O: Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer 46(18): 3417-3424, 2010.
70. Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, Hu SY, Zhao WL, Wang J, Lou GL and Li Z: An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med 9: 157, 2011.
71. Nunes J, Naymark M, Sauer L, Muhammad A, Keun H, Sturge J, Stebbing J, Waxman J and Pchejetski D: Circulating sphingosine-1-phosphate and erythrocyte sphingosine kinase-1 activity as novel biomarkers for early prostate cancer detection. Br J Cancer 106(5): 909-915, 2012.
72. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S and Nakamura SI: Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 278(47): 46832-46839, 2003.
73. Hofmann LP, Ren S, Schwalm S, Pfeilschifter J and Huwiler A: Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol Chem 389(11): 1399-407, 2008.
74. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman RE, Collier C, Zhang M, Satin LS, Merrill AH, Jr, Milstien S and Spiegel S: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280(44): 37118-37129, 2005.
75. Van Brocklyn JR, Letterle CA, Snyder PJ and Prior TW: Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: Role of ERK MAP kinase and phosphatidylinositol 3-kinaseβ. Cancer Lett 181(2): 195-204, 2002.
76. Van Brocklyn JR, Young N and Roof R: Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett 199(1): 53-60, 2003.
77. Young N and Van Brocklyn JR: Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res 313(8): 1615-1627, 2007.
78. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ and Prior TW: Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: Roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 64(8): 695-705, 2005.
79. Vann LR, Payne SG, Edsall LC, Twitty S, Spiegel S and Milstien S: Involvement of sphingosine kinase in TNF-alphastimulated tetrahydrobiopterin biosynthesis in C6 glioma cells. J Biol Chem 277(15): 12649-12656, 2002.
80. Yoshida Y, Nakada M, Sugimoto N, Harada T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Yachie A, Takuwa Y and Hamada JI: Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. Int J Cancer 126(10): 2341-2352, 2010.
81. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS and Li M: Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 14(21): 6996-7003, 2008.
82. Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A and Van Brocklyn JR: The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells. J Neuro-Oncol 102: 353-366, 2011.
83. Anelli V, Gault CR, Cheng AB and Obeid LML: Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 283(6): 3365-3375, 2008.
84. Quint K, Stiel N, Neureiter D, Schlicker HU, Nimsky C, Ocker M, Strik H and Kolodziej MA: The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumor Biology 35(9): 8979-8989, 2014.
85. Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, McDonald KL and Don AS: A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem 288(52): 37355-37364, 2013.
86. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK and Smith CD: Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther 318(2): 596-603, 2006.
87. Pyne S, Bittman R and Pyne NJ: Sphingosine kinase inhibitors and cancer: Seeking the golden sword of Hercules. Cancer Res 71(21): 6576-6582, 2011.
88. Delgado A, Casas J, Llebaria A, Abad JL and Fabrias G: Inhibitors of sphingolipid metabolism enzymes. Biochim Biophys Acta 1758(12): 1957-1977, 2006.
89. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK and Smith CD: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63(18): 5962-5969, 2003.
90. Edsall, LC, Van Brocklyn JR, Cuvillier O, Kleuser B and Spiegel S: N, N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: Modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37(37): 12892-12898, 1998.
91. Yatomi Y, Ruan F, Megidish T, Toyokuni T, Hakomori S and Igarashi YN: N, N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 35(2): 626-633, 1996.
92. Cingolani F, Casasampere M, Sanllehi P, Casas J, Bujons J and Fabrias G: Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J Lipid Res 55(8): 1711-1720, 2014.
93. Igarashi Y, Hakomori S, Toyokuni T, Dean B, Fujita S, Sugimoto M, Ogawa T, El-Ghendy K and Racker E: Effect of chemically well-defined sphingosine and its methyl derivatives on protein kinase C and src kinase activities. Biochemistry, 28(17): 6796-6800, 1989.
94. Chun J and Hartung HP: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 33(2): 91-101, 2010.
95. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, Aradhye S and Burtin P: Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9(11): 883-897, 2010.
96. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G and Radue EW: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11): 1124-1140.
97. Brunkhorst R, Vutukuri R and Pfeilschifter W: Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci 8: 283, 2014.
98. Sonoda Y, Yamamoto D, Sakurai S, Hasegawa M, Aizu-Yokota E, Momoi T and Kasahara T: FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem Biophys Res Commun 281(2): 282-288, 2001.
99. Dawson G and Qin J: Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants. Biochem Biophys Res Commun 404(1): 321-323, 2011.
100. Zollinger M, Gschwind HP, Jin Y, Sayer C, Zecri F and Hartmann S: Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: A case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos 39(2): 199-207, 2011.
101. Canals D, Perry DM, Jenkins RW and Hannun YA: Drug targeting of sphingolipid metabolism: Sphingomyelinases and ceramidases. Br J Pharmacol 163: 694-712, 2011.
102. Pankova-Kholmyansky I and Flescher E: Potential new antimalarial chemotherapeutics based of sphingolipid metabolism. Chemotherapy 52: 205-209, 2006.
103. Labaied M, Dagan A, Dellinger M, Geze M, Egee S, Thomas SL, Wang C, Gatt S and Grellier P: Anti-plasmodium activity of ceramide analogs. Malaria J 3: 49, 2004.
104. Sharma N: Inhibiton of tumor cell growth by mefloquine via multimechanistic effects involving increased cellular stress, inhibition of autophagy, and impairment of cellular energy metabolism. Ph.D. Thesis, University of Southern California, 3564014, 2013.
105. Petersen NHT, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lonborg A, Vindelov SD, Hanahan D, Arenz C, Ejsing CS, Kirkegaard T, Rohde M, Nylandsted J and Jaattela M: Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 24: 379-393, 2013.
106. Sun WY, Abeynaike LD, Escarbe S, Smith CD, Pitson SM, Hickey MJ and Bonder CS: Rapid histamine-induced neutrophil recruitment is sphingosine kinase-1 dependent. Am J Pathol 180: 1740-1750, 2012.
107. Senchenkov A, Litvak DA and Cabot MC: Targeting ceramide metabolism - A strategy for overcoming drug resistance. J Natl Cancer Inst 93: 347-357, 2001.
108. Futerman AH (Ed.): Ceramide Signaling. Kluwer Academic, Plenum Publishers 2002.
109. Alemany R, Kleuser B, Ruwisch L, Danneberg K, Lass H, Hashemi R, Spiegel S, Jacobs KH and zu Heringdorf D: Depolarization induces rapid and transient formation of intracellular sphingosine-1-phosphate. FEBS Lett 509: 239-244, 2001.
110. Moussavi M, Assi K, Gomez-Munoz A and Salh B: Curcumin mediates ceramide generation via the de novo pathway in colon cancer cells. Carcinogenesis 27: 1636-1644, 2006.
111. Huang J, Huang K, Lan T, Xie X, Shen X, Liu P and Huang H: Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway. Molecular and Cellular Endocrinology 365(2): 231-240, 2013.
112. Kizhakkayil J, Thayyullathil F, Chathoth S, Hago A, Patel M and Galadari S: Glutathione regulates caspase-dependent ceramide production and curcumin-induced apoptosis in human leukemic cells. Free Radic Biol Med 52(9): 1854-1864, 2012.
113. Shakor AB, Atia M, Ismail IA, Alshehri A, El-Refaey H, Kwiatkowska K and Sobota A: Curcumin induces apoptosis of multidrug-resistant human leukemia HL60 cells by complex pathways leading to ceramide accumulation. Biochim Biophys Acta 1841(12): 1672-1682, 2014.
114. Lim KG, Gray AI, Pyne S and Pyne NJ: Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol 166(5): 1605-1616, 2012.
115. Ulrich S, Huwiler A, Loitsch S, Schmidt H and Stein JM: De novo ceramide biosynthesis is associated with resveratrolinduced inhibition of ornithine decarboxylase activity. Biochemical Pharmacology 74(2): 281-289, 2007.
116. Muscoli C, Doyle T, Dagostino C, Bryant L, Chen Z, Watkins LR, Ryerse J, Bieberich E, Neumman W and Salvemini D: Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J Neurosci 30(46): 15400-15408, 2010.
117. Ndengele MM, Cuzzocrea S, Masini E, Vinci MC, Esposito E, Muscoli C, Petrusca DN, Mollace V, Mazzon E, Li D, Petrache I, Matuschak GM and Salvemini D: Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J Pharmacol Exp Ther 329(1): 64-75, 2009.
118. Kono K, Tanaka M, Ono Y, Hosoya T, Ogita T and Kohama T: S-15183a and b, new sphingosine kinase inhibitors, produced by a fungus. J Antibiot 54(5): 415-420, 2001.
119. Xiang Y, Asmussen G, Booker M, Hirth B, Kane JL Jr, Liao J, Noson KD and Yee C: Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett 19(21): 6119-6121, 2009.
120. Xiang Y, Hirth B, Kane JL Jr., Liao J, Noson KD, Yee C, Asmussen G, Fitzgerald M, Klaus C and Booker M: Discovery of novel sphingosine kinase-1 inhibitors. Part 2. Bioorg Med Chem Lett 20(15): 4550-4554, 2010.
121. Kono K, Tanaka M, Ogita T and Kohama T: Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot 53(8): 759-764, 2000.
122. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S and Spiegel S: A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112(4): 1382-1391, 2008.
123. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD and Voelkel-Johnson C: The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo. Mole Cancer Ther 14(12): 2744-2752, 2015.
124. Neubauer HA and Pitson SM: Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J 280(21): 5317-5336, 2013.
125. Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE and Smith CD: Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression. Mol Cancer Res 13(12): 1591-1601.
126. Bektas M, Johnson SP, Poe WE, Bigner DD and Friedman HS: A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells. Cancer Chemother Pharmacol 64(5): 1053-1058, 2009.
127. Kapitonov D, Allegood JC, Mitchell C, Hait NC, Almenara JA, Adams JK, Zipkin RE, Dent P, Kordula T, Milstien S and Spiegel S: Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res 69(17): 6915-6923, 2009.
128. Vann LR, Payne SG, Edsall LC, Twitty S, Spiegel S and Milstien S: Involvement of sphingosine kinase in TNF-alphastimulated tetrahydrobiopterin biosynthesis in C6 glioma cells. J Biol Chem 277(15): 12649-12656, 2002.
129. Zhang H, Li W, Sun S, Yu S, Zhang M and Zou F: Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signalregulated kinase. Cell Prolif 45(2): 167-175, 2012.
130. Estrada-Bernal A, Palanichamy K, Ray Chaudhury A and Van Brocklyn JR: Induction of brain tumor stem cell apoptosis by FTY720: A potential therapeutic agent for glioblastoma. Neuro Oncol 14(4): 405-415, 2012.
131. Zhang L, Wang H, Ding K and Xu J: FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. Toxicol Lett 236(1): 43-59, 2015.
132. Zhang L, Wang H, Zhu J, Ding K and Xu J: FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol 35(11): 10707-10714, 2014.
133. Kolodziej M, Al-Barim B, Stein M, Reinges M, Uhle F, Quint K and Uhl E: The strong antiproliferative effects of FTY720 (fingolimod) in glioblastoma cells in vitro. 65th Annual Meeting of the German Society of Neurosurgery (DGNC) German Society of Neurosurgery (DGNC), 2014.
134. Young N, Pearl DK and Van Brocklyn JR: Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res 7(1): 23-32, 2009.
135. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind JS and Spiegel S: Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381: 800-803, 1996.
136. Mora R, Dokic I, Kees T, Huber CM, Keitel D, Geibig R, Brugge B, Zentgraf H, Brady NR and Regnier-Vigouroux A: Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma. Glia 58(11): 1364-1383, 2010.
137. Jessup CF, Bonder CS, Pitson SM and Coates PT: The sphingolipid rheostat: A potential target for improving pancreatic islet survival and function. Endocr Metab Immune Disord Drug Targets 11(4): 26272, 2011.
138. Sordillo PP, Sordillo DC and Helson L: The prolonged QT Interval: Role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways. In Vivo 29(6): 619-636, 2015.
139. Freed JK, Hockenberry JC and Gutterman DD: Manipulation of the sphingolipid rheostat alters the mediator of flow-induced dilation in the human microcirculation. Circulation 130(Suppl 2): A16304, 2014.
140. Haass NK Nassif N and McGowan EM: Switching the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. Biomed Res Int, 2015.
141. Guan H, Song L, Cai J, Huang Y, Wu J, Yuan J, Li J and Li M: Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells. PLoS One 6(5): E19946, 2011.
142. Illuzzi G, Bernacchioni C, Aureli M, Prioni S, Frera G, Donati C, Valsecchi M, Chigorno V, Bruni P, Sonnino S and Prinetti A: Sphingosine kinase mediates resistance to the synthetic retinoid N-(4-hydroxyphenyl) retinamide in human ovarian cancer cells. Journal of Biological Chemistry 285(24): 18594-18602, 2010.
143. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS and Kundra V: Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3): 225-238, 2006.
144. Bieberich, E: Ceramide signaling in cancer and stem cells. Future Lipidol 3: 273-300, 2008.
145. Taniguchi M, Kitatani K, Kondo T, Hashimoto-Nishimura M, Asano S, Hayashi A, Mitsutake S, Igarashi Y, Umehara H, Takeya H and Kigawa J: Regulation of autophagy and its associated cell death by "sphingolipid rheostat": Reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J Biol Chem 287(47): 39898-39910, 2012.
146. Schwartz GK, Ward D, Saltz L, Saltz L, Casper ES, Spiess T, Mullen E, Woodworth J, Venuti R, Zervos P, Storniolo AM and Kelsen DP: A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 3(4): 537-543, 1997.
147. Kedderis LB, Bozigian HP, Kleeman JM, Hall RL, Palmer TE, Harrison SD and Susick RL: Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam Appl Toxicol 25(2): 201-21, 1995.
148. Li QF, Yan J, Zhang K, Yang YF, Xiao FJ, Wu CT, Wang H and Wang LS: Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+cells sensitive and resistant to STI571 through down-regulation Mcl-1. Biochem Biophys Res Commun 405(1): 31-36, 2011.
149. Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, Smith AD, Urquhart G, Bielawski J, Finnegan M and Petty R: Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer 15(1): 762, 2015.
150. Sordillo LA, Sordillo PP and Helson L: Curcumin for the treatment of glioblastoma. Anticancer Res 35(12): 6373-6378, 2015.
151. Noack J, Choi J, Richter K, Kopp-Schneider A and Regnier-Vigouroux A: A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy. Cell Death Dis 5: E1425, 2014.
152. Riccitelli E, Giussani P, Di Vito C, Condomitti G, Tringali C, Caroli M, Galli R, Viani P and Riboni L: Extracellular sphingosine-1-phosphate: A novel actor in human glioblastoma stem cell survival. PLoS One 8(6): E682292013, 2013.
153. Harris BN, Masood R and Sinha UK: Sphk1 expression and survival outcomes in squamous cell carcinoma of the oral cavity. J Cancer Therapy 4: 704-708, 2013.
154. Camgoz A, Gencer EB, Ural AU, Avcu F and Baran Y: Roles of ceramide synthase and ceramide clearance genes in nilotinib induced cell death in chronic myeloid leukemia cells. Leuk Lymphoma 52(8): 1574-1584, 2011.
155. Baran Y, Camgoz A, Gencer E, Ural A and Avcu F: A novel mechanism of nilotinib-induced apoptosis, bioactive sphingolipids. Haematologica 95: 528, 2010.
156. Gencer EB, Ural AU, Avcu F and Baran Y: A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Ann Hematol 90: 1265-1275, 2011.